CEO Update - 17 June 2024

General election banner for newscast (1).png

Last week saw the key parties launch their General Election manifestoes. Each party had policies of interest to our sector and the team has done a detailed breakdown. This week sees a set piece hosting debate with the core parties talking about their approach to science and innovation at a live hustings at the Royal Society on Wednesday the BIA will be going and if you wish to view the live stream.

Remember we will summarise the whole campaign in a highlights package via our webinar one week before polling day. We will look at what we’ve learned from the campaign and consider what various election outcomes could mean for the sector and its stakeholders. 

Influencing report.png

Between April and June 2024, BIA represented the life science sector to Ministers and senior policymakers. With a snap election on 4 July, BIA focused on preparing for the next government, postponing Parliament Day to autumn and limiting official engagements due to pre-election sensitivity.

Influencing report - 6 meetings.png

 

Influencing report icons (200 × 200px) (1).png

 

Influencing report icons letters.png

 

We've hosted a UK-Swiss summit on engineering biology, met the Lord Mayor of London to discuss future sector skills, and engaged with parliamentarians on improving access to rare disease treatments. BIA also worked with London Economics on R&D tax credits, contributed to NHS secure data environments, and influenced UK clinical trials regulation with the MHRA.

Read more in our report which summarises BIA’s recent activities.

London Stock Exchange and JP Morgan London conferences on life sciences

Away from the campaign trail, the buzz about UK life sciences continues in city events hosted by the London Stock Exchange and JP Morgan this week. It's always good to see emerging UK companies speaking and the opportunities they present provide the backdrop to and necessity for the ongoing Mansion House agenda to get more UK-based investment to back UK scaling and growing companies.

LightOx investment

Telling the stories of companies like LightOx, a Newcastle-based BIA member who raised £1.5 million last week to help develop a ground-breaking treatment for patients suffering from early-stage oral cancer, brings what our sector does to life. Their oral gel is activated by a light device that targets a serious pre-cancerous condition called oral epithelial dysplasia. 

Founded by Carrie Ambler, professor of biosciences at Durham University and serial entrepreneur Dr Sam Whitehouse, the company’s raise last week was led by the GMC Life Sciences Fund by Praetura. It is a collaborative fund managed by Praetura Ventures and made up of Bruntwood SciTech, Cheshire and Warrington Local Enterprise Partnership and Greater Manchester Combined Authority.

LightOx’s existing investors have also contributed, including Newcastle’s Northstar Ventures. It just goes to show how innovative funding rounds are being put together through 2024 and in all parts of the UK. 

US BIOSECURE Act delayed

In a surprise move to many in Washington DC, the proposed BIOSECURE Act in the USA was not included in the final basket of amendments to the National Defense Authorization Act (NDAA) this year. The proposals were intended to remove Chinese companies from the supply chain for biotech companies seeking to do business in the USA.

The NDAA had been seen as the likeliest route for the BIOSECURE Act to make it onto the statute. However last week’s news doesn’t mean that it won't be attached to another Bill nor that biotech is no longer in the central focus of the national security policy community in the USA. There are several other mechanisms in play that are key to understanding the changing strategic picture both in the USA, Europe and the UK. It’s a topic I’m looking forward to discussing with many of you at the Life Science Leadership Summit today and tomorrow

New Scientist on Deep Biotech

Check out the New Scientist campaign on Life Sceince Innovation 2024 this month for a piece by BIA's Senior Policy and Public Affairs Manager, Linda Bedenik, on how Deep Biotech is leading the way on sustainability

Longitude Prize 

In 2014, Challenge Works initiated a competition for the UK public to decide the focus of a new Longitude Prize. The choice of challenges was presented on the One Show on the BBC. The British public voted that tackling AMR was the challenge the prize should help solve.

Following a decade of developments, and entries from more than 250 teams worldwide, the £8 million Longitude Prize on AMR has been awarded to the PA-100 AST System from Sysmex Astrego. The goal is to replace the two- to three-day lab test process that doctors and patients must currently endure and end “just in case” prescribing that is prevalent as a result, which promotes the development of antibiotic resistance. It is a testament to the open innovation ethos to see a Swedish company win this UK-inspired prize. 

 

Steve Bates Headshot.png

 

 

Steve Bates OBE
CEO, BioIndustry Association

More news and updates 

ImmuONE is celebrating triple triumph at the inspiring herts awards 2024

We’re proud to announce that ImmuONE took home the prestigious award for ‘Business of the Year – North Herts’, which was awarded to us for consistent growth, robust financial performance, and unwavering commitment to staff and innovation. From the pool of winners, there was also a special recognition category which honoured ImmuONE with the ‘Inspiring Business of the Year’ award for making the biggest innovation in Hertfordshire.

Cryoport systems officially launches global supply chain hub in Stevenage

Cryoport, Inc a global leader in innovative supply chain solutions for the cell and gene therapy industry, is thrilled to announce the official launch of the Cryoport Systems state-of-the-art Global Supply Chain Hub in Stevenage, U.K.

Microbiotica to present positive update on manufacturing progress of its live biotherapeutic products

Microbiotica, a biopharma company developing a pipeline of orally-delivered precision microbiome medicines announces that Adam Wilkinson, its Vice President of Pre-Clinical Development, will present an overview of the company’s successful product manufacturing campaigns ahead of its forthcoming melanoma and ulcerative colitis clinical studies at the 9th Microbiome Movement Drug Development Summit, on 11 July, in Boston, USA, together with Claire Derlot, CBO from its GMP manufacturing partner Biose Industrie.

Milner Institute celebrates success of 2024 Pitch Day and therapeutics symposium

The Milner Therapeutics Institute were delighted to host two sell-out events in Cambridge that brought academics, investors, pharma and biotech companies together.

CEO Update - 8 July 2024

It is a fantastic way to start the week with news of Europe’s largest Series A biotech spin-out this year from the UK. Congratulations to Myricx Bio, an Imperial College London and Francis Crick Institute spin-out company focusing on a novel class of payloads for antibody-drug conjugates (ADCs), for announcing their Series A financing of £90 million.

Moa harvests global deal for new herbicide

Moa Technology has signed a major research and commercial agreement with Australian ag giant Nufarm. The deal will see Moa receiving receive upfront payments, milestone development payments and royalties in return for Nufarm gaining exclusive access to a product in one of Moa's breakthrough novel mode of action areas.

Brandon Capital's vision for a transcontinental life science axis

Jonathan Tobin, Partner at Brandon Capital, discusses the firm's recent close of its sixth fund at A$270 million, bringing its total assets under management to over A$1.25 billion. He also explores how Brandon Capital is strategically connecting Australia, New Zealand, the UK, and the US.

Myricx Bio announces £90 million Series A financing to advance its novel NMTi-ADC therapeutics into clinical development

£90 million ($114 million) series A co-led by new leading life science investors Novo Holdings and Abingworth; additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners.

PIR International interview with Anja Harmeier, CEO, Rewind Therapeutics

In this blog, PIR International presents an interview with Anja Harmeier, CEO of Rewind Therapeutics, as part of their BioLeader interview series.

NCIMB Ltd kicks off innovative enzyme technology development project

Aberdeen-based biotechnology company NCIMB has kicked-off a new research project to demonstrate novel enzyme technology with an exciting array of potential applications in the pharmaceutical, food & drink and environmental sectors.

Promising results from cardiac fibrosis studies with MRX1

Ananda Developments PLC, a clinical-stage life sciences company focused on the development of CBD based therapies for the treatment of a range of complex inflammatory pain conditions, is delighted to share promising results from recent preclinical studies investigating the efficacy of MRX1 (Patent Pending) in treating cardiac fibrosis and heart failure with preserved ejection fraction (HFpEF).

Valneva Scotland appoints science communications consultancy, Perceptive Communicators

Glasgow-based specialist communications consultancy, Perceptive Communicators, has announced its appointment to provide strategic communications services for Valneva Scotland.

More within